The U.S. Food and Drug Administration has given St. Paul, Minn.-based Smiths Medical 510(k) clearance to market its CADD-Solis Pain Management system with programmed intermittent bolus and patient controlled analgesics delivery, according to a news release.
The new customizable system will help with epidural analgesia during labor and delivery and postoperative pain management, according to the news release.
Traditionally, labor analgesia is administered through manual bolus injections from a healthcare provider or continuous infusions. The new system automatically administers bolus injections that the patient can now supplement if he or she desires.
More Articles on FDA Approvals:
FDA Approves Gore Medical's Viabhan Endoprosthesis Devices Use Expansion
FDA Names GS1 First Accredited Issuing Agency for UDIs
Reverse Medical Receives 501(k) Clearance from FDA on Micro Vascular Plug System